The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force
Abstract
BACKGROUND: Cardiovascular disease (CVD) is the leading cause of death in the United States. PURPOSE: To update a systematic review about the benefits of aspirin for the primary prevention of cardiovascular events in adults aged 40 years or older and to evaluate effect modification in subpopulations. DATA SOURCES: MEDLINE, PubMed, Cochrane Central Register of Controlled Trials (January 2008 to January 2015), and Cochrane Database of Systematic Reviews. STUDY SELECTION: Two investigators independently reviewed 3396 abstracts and 65 articles according to prespecified criteria. All included trials evaluated aspirin for the primary prevention of cardiovascular events. DATA EXTRACTION: Two investigators assessed study quality; data were abstracted by 1 reviewer and checked by a second. DATA SYNTHESIS: Two good-quality and 9 fair-quality randomized, controlled trials were identified. In analyses of all doses, aspirin reduced the risk for nonfatal myocardial infarction (MI) (relative risk [RR], 0.78 [95% CI, 0.71 to 0.87]) but not nonfatal stroke; aspirin showed little or no benefit for all-cause or cardiovascular mortality. Benefits began within the first 5 years. Older adults achieved greater relative MI reduction, but no other effect modifications were found in analyzed subpopulations. In trials with aspirin doses of 100 mg or less per day, the reduction in nonfatal MI benefit persisted (absolute risk reduction, 0.15 to 1.43 events per 1000 person-years) and a 14% reduction in nonfatal stroke benefit was noted, but no benefit was found for all-cause mortality (RR, 0.95 [CI, 0.89 to 1.01]) or cardiovascular mortality (RR, 0.97 [CI, 0.85 to 1.10]). LIMITATION: Evidence for aspirin in primary prevention is heterogeneous and limited by rare events and few credible subgroup analyses. CONCLUSION: The beneficial effect of aspirin for the primary prevention of CVD is modest and occurs at doses of 100 mg or less per day. Older adults seem to achieve a greater relative MI benefit. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., de Ferranti, S., Després, J.-P., Fullerton, H. J., Howard, V. J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000152 · Cited by 5,797
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Meschia, J. F., Bushnell, C., Boden-Albala, B., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Elkind, M. S. V., Fornage, M., et al. (2014) · Stroke · doi:10.1161/str.0000000000000046 · Cited by 2,650
Final Report on the Aspirin Component of the Ongoing Physicians' Health Study
Steering Committee of the Physicians' Health Study Research Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198907203210301 · Cited by 2,264
Mosca, L., Benjamin, E. J., Berra, K., Bezanson, J. L., Dolor, R. J., Lloyd-Jones, D. M., Newby, L. K., Piña, I. L., Roger, V. L., Shaw, L. J., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820faaf8 · Cited by 2,143
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
Ridker, P. M., Cook, N. R., Lee, I.-M., Gordon, D., Gaziano, J. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050613 · Cited by 1,945
Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318235eb4d · Cited by 1,759
Goldstein, L. B., Bushnell, C. D., Adams, R. J., Appel, L. J., Braun, L. T., Chaturvedi, S., Creager, M. A., Culebras, A., Eckel, R. H., Hart, R. G., et al. (2011) · Stroke · doi:10.1161/str.0b013e3181fcb238 · Cited by 1,306
Randomised trial of prophylactic daily aspirin in British male doctors
Peto, R., Gray, R., Collins, R., Wheatley, K., Hennekens, C., Jamrozik, K., Warlow, C., Hafner, B., Thompson, E., Norton, S., et al. (1988) · BMJ · doi:10.1136/bmj.296.6618.313 · Cited by 1,166
Roncaglioni, M. C. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03539-x · Cited by 999
Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., Lee, R., Bancroft, J., MacEwan, S., Shepherd, J., et al. (2008) · BMJ · doi:10.1136/bmj.a1840 · Cited by 977
Authors/Task Force Members: Joep Perk (Chairperson) (Sweden)*, G. D. B. (. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312450228 · Cited by 863
Berger, J. S., Roncaglioni, M. C., Avanzini, F., Pangrazzi, I., Tognoni, G., & Brown, D. L. (2006) · JAMA · doi:10.1001/jama.295.3.306 · Cited by 789
Fu, R., Gartlehner, G., Grant, M., Shamliyan, T., Sedrakyan, A., Wilt, T. J., Griffith, L., Oremus, M., Raina, P., Ismaila, A., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.08.010 · Cited by 730
Fowkes, F. G. R. (2010) · JAMA · doi:10.1001/jama.2010.221 · Cited by 624
JBS3 Board (2014) · Heart · doi:10.1136/heartjnl-2014-305693 · Cited by 608
Validation of the Atherosclerotic Cardiovascular Disease Pooled Cohort Risk Equations
Muntner, P., Colantonio, L. D., Cushman, M., Goff, D. C., Howard, G., Howard, V. J., Kissela, B., Levitan, E. B., Lloyd-Jones, D. M., & Safford, M. M. (2014) · JAMA · doi:10.1001/jama.2014.2630 · Cited by 603
U.S. Preventive Services Task Force* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-6-200903170-00008 · Cited by 533
DeFilippis, A. P., Young, R., Carrubba, C. J., McEvoy, J. W., Budoff, M. J., Blumenthal, R. S., Kronmal, R. A., McClelland, R. L., Nasir, K., & Blaha, M. J. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1281 · Cited by 515
Statins: new American guidelines for prevention of cardiovascular disease
Ridker, P. M., & Cook, N. R. (2013) · The Lancet · doi:10.1016/s0140-6736(13)62388-0 · Cited by 481
Kassoff, A. (1992) · JAMA · doi:10.1001/jama.1992.03490100090033 · Cited by 481
Primary and Secondary Prevention of Cardiovascular Disease
Vandvik, P. O., Lincoff, A. M., Gore, J. M., Gutterman, D. D., Sonnenberg, F. A., Alonso-Coello, P., Akl, E. A., Lansberg, M. G., Guyatt, G. H., & Spencer, F. A. (2012) · Chest · doi:10.1378/chest.11-2306 · Cited by 476
Ferreira-González, I., Permanyer-Miralda, G., Domingo-Salvany, A., Busse, J. W., Heels-Ansdell, D., Montori, V. M., Akl, E. A., Bryant, D. M., Alonso-Coello, P., Alonso, J., et al. (2007) · BMJ · doi:10.1136/bmj.39136.682083.ae · Cited by 473
Fortmann, S. P., Burda, B. U., Senger, C. A., Lin, J. S., & Whitlock, E. P. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-12-201312170-00729 · Cited by 442
De Berardis, G., Sacco, M., Strippoli, G. F. M., Pellegrini, F., Graziano, G., Tognoni, G., & Nicolucci, A. (2009) · BMJ · doi:10.1136/bmj.b4531 · Cited by 395
Credibility of claims of subgroup effects in randomised controlled trials: systematic review
Sun, X., Briel, M., Busse, J. W., You, J. J., Akl, E. A., Mejza, F., Bala, M. M., Bassler, D., Mertz, D., Diaz-Granados, N., et al. (2012) · BMJ · doi:10.1136/bmj.e1553 · Cited by 395
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Z., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs254 · Cited by 390
Sacco, M., Pellegrini, F., Roncaglioni, M. C., Avanzini, F., Tognoni, G., Nicolucci, A., & on behalf of the PPP Collaborative Group (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3264 · Cited by 381
Kavousi, M., Leening, M. J. G., Nanchen, D., Greenland, P., Graham, I. M., Steyerberg, E. W., Ikram, M. A., Stricker, B. H., Hofman, A., & Franco, O. H. (2014) · JAMA · doi:10.1001/jama.2014.2632 · Cited by 351
Deaths: leading causes for 2010.
Heron, M. P. (2013) · PubMed · Cited by 317
Cook, N. R., Lee, I.-M., Zhang, S. M., Moorthy, M. V., & Buring, J. E. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-2-201307160-00002 · Cited by 315
Ikeda, Y., Shimada, K., Teramoto, T., Uchiyama, S., Yamazaki, T., Oikawa, S., Sugawara, M., Ando, K., Murata, M., Yokoyama, K., et al. (2014) · JAMA · doi:10.1001/jama.2014.15690 · Cited by 301
Seshasai, S. R. K. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.628 · Cited by 272
Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes
Pignone, M., Alberts, M. J., Colwell, J. A., Cushman, M., Inzucchi, S. E., Mukherjee, D., Rosenson, R. S., Williams, C. D., Wilson, P. W., & Kirkman, M. S. (2010) · Diabetes Care · doi:10.2337/dc10-0555 · Cited by 242
Whitlock, E. P., Burda, B. U., Williams, S. B., Guirguis-Blake, J. M., & Evans, C. V. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2112 · Cited by 227
Self-citationMeta-Analysis of Multiple Primary Prevention Trials of Cardiovascular Events Using Aspirin
Bartolucci, A. A., Tendera, M., & Howard, G. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.02.325 · Cited by 186
Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease
Raju, N., Sobieraj-Teague, M., Hirsh, J., O'Donnell, M., & Eikelboom, J. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.01.018 · Cited by 169
De Berardis, G., Sacco, M., Evangelista, V., Filippi, A., Giorda, C. B., Tognoni, G., Valentini, U., Nicolucci, A., & ACCEPT-D Study Group (2007) · Trials · doi:10.1186/1745-6215-8-21 · Cited by 161
Chubak, J., Whitlock, E. P., Williams, S. B., Kamineni, A., Burda, B. U., Buist, D. S. M., & Anderson, M. L. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2117 · Cited by 160
Self-citationGuideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events
Pursnani, A. K., Massaro, J. M., D’Agostino, R. B., O’Donnell, C. J., & Hoffmann, U. (2015) · JAMA · doi:10.1001/jama.2015.7515 · Cited by 151
Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis
Zhang, C., Sun, A., Zhang, P., Wu, C., Zhang, S., Fu, M., Wang, K., Zou, Y., & Ge, J. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.09.029 · Cited by 150
Berger, J. S., Lala, A., Krantz, M. J., Baker, G. S., & Hiatt, W. R. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.04.006 · Cited by 145
Meade, T. W., & Brennan, P. J. (2000) · BMJ · doi:10.1136/bmj.321.7252.13 · Cited by 117
Kjeldsen, S. E., Kolloch, R. E., Leonetti, G., Malliond, J.-M., Zanchetti, A., Elmfeldt, D., Warnold, I., & Hansson, L. (2000) · Journal of Hypertension · doi:10.1097/00004872-200018050-00017 · Cited by 116
Zalewska, J. (2009) · PubMed · Cited by 95
Nelson, M. R., Reid, C. M., Beilin, L. J., Donnan, G. A., Johnston, C. I., Krum, H., Storey, E., Tonkin, A. M., & McNeil, J. J. (2003) · Drugs & Aging · doi:10.2165/00002512-200320120-00004 · Cited by 72
Butalia, S., Leung, A. A. C., Ghali, W. A., & Rabi, D. M. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-25 · Cited by 61
Younis, N., Williams, S. D., Ammori, B. J., & Soran, H. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003792538 · Cited by 45
Stavrakis, S., Thadani, U., Azar, M., Wayangankar, S. A., & Stoner, J. A. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181f1fba8 · Cited by 41
Aspirin overutilization for the primary prevention of cardiovascular disease
VanWormer, J. J., Miller, A., & Rezkalla, S. H. (2014) · Clinical Epidemiology · doi:10.2147/clep.s72032 · Cited by 22
Matthys, F., Backer, T. L. M. D., Backer, G. D., & Stichele, R. V. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312472077 · Cited by 20
Vitamin and Mineral Supplements in the Primary Prevention of Cardiovascular Disease and Cancer
Fortmann, S. P., Whitlock, E. P., & Burda, B. U. (2014) · Annals of Internal Medicine · doi:10.7326/l14-5009-5 · Cited by 18
Self-citationAspirin and Antiplatelet Drugs in the Prevention of Cardiovascular Complications of Diabetes
Zanchetti, A. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6_19 · Cited by 14
Cited by
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
Stroke risk factors, genetics, and prevention
Boehme, A. K., Esenwa, C., & Elkind, M. S. V. (2017) · Circulation Research · doi:10.1161/circresaha.116.308398 · Cited by 1,952
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.010 · Cited by 1,896
The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381
Metadata
- Authors
- Guirguis-Blake, J. M., Evans, C. V., Senger, C. A., O'Connor, E. A., & Whitlock, E. P.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-06-21
- Volume
- 164
- Issue
- 12
- Pages
- 804-813
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1810855509
- Cited by
- 260
- References
- 61
- FWCI
- 36.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.